Glucagon

  • Description and indication for use

    Glucagon is a pancreatic hormone.  Glucagon stimulates cyclic AMP in the liver and adipose tissue, initiating gluconeogenesis and glycogenolysis, resulting in an increase in blood sugar.  Parenteral administration produces relaxation of the smooth muscle of the gastrointestinal tract and bronchial tree.  Glucagon increases the force of contraction of the heart, with little or no effect on heart rate.

    Glucagon is effective in the treatment of hypoglycaemia due to severe insulin reactions and hypoglycaemia when glucose infusion is unavailable or there is no response to routine treatment.

    The onset of action of Glucagon is 5 to 20 minutes, the half-life being only 3 to 6 minutes, with duration of action usually 1 to 2 hours.  Glucagon is inactivated mainly in the liver and kidney.

    Dose

    1 unit = 1 mg.

    IV, IM and SC:

    300 micrograms/kg/dose (0.3 mg/kg/dose) may be repeated in 20 minutes if necessary.  

    (Maximum dose = 1 mg)

    IV infusion:

    5 to 10 micrograms/kg/hour.

    Reconstitution/Dilution

    Vial = 1 unit (1 mg).  Glucagon should only be reconstituted using the diluting solution provided = 1 mL of reconstituted solution = 1 mg/mL

    IV, IM and SC:    

    Use 1 mg/mL solution.

    IV infusion:        

    Withdraw prescribed amount of Glucagon and make up to ordered volume with Glucose 10%.

    Once diluted in Glucose, the solution is stable for 8 hours only.

    DRUG HOW TO MAKE UP DOSE EQUIVALENT DOSE RANGE
    Glucagon 250 microgram/kg in 25 mL Glucose 10% 1 mL/hr = 10 microgram/kg/hr 5 to 10 microgram/kg/hr

     

    Route and method of administration

    IV, IM and SC:    

    STAT using 1 mg/mL solution.

    More than 1 IM site may be required if maximum dose is to be given.

    IV infusion:        

    Infuse at prescribed rate via syringe pump.

    Side effects

    Nausea, vomiting.

    Tachycardia.

    Rebound hypoglycaemia.

    Contraindications

    Hypersensitivity to protein compounds.

    Patients who have decreased Glycogen stores (Do not use in IUGR/SGA).

    Patients with Insulinoma.

    Incompatibilities

    Administer alone.

    Drug interactions

    No known interactions.

    Nursing responsibilities

    Obtain blood glucose levels as condition indicates.

    Monitor clinical status continuously.

    Avoid giving boluses when giving infusion.

    Infusion:  Check that rate ordered corresponds with appropriate dose required (mcg/kg/hr).

Disclaimer:  This Drug information was designed for use by PIPER Neonatal. Whilst great care has been taken to check the information is accurate, it is possible that errors may have been missed. Furthermore, dosage schedules are continually being revised and new side effects recognised. For these reasons, the reader is strongly advised to consult the drug companies' printed information before administering any of the drugs recommended in this book.
Most drugs in this document are appropriate only for specialist use in hospitals.  A number of drugs should only be used in consultation with the appropriate Paediatric subspecialist. 

Note: The electronic version of this guideline is the version currently in use.  Any printed version cannot be assumed to be current. Printed copies of this document are valid for